Search Results - "Armario‐Hita, José C."
-
1
Trend of relevant contact allergens of the feet in Spain over a period of 10 years
Published in Contact dermatitis (01-04-2020)“…Introduction Allergic contact dermatitis (ACD) of the feet accounts for approximately 10% of all patch tested patients. Objective To study the clinical profile…”
Get full text
Journal Article -
2
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi‐Criteria Decision Analysis
Published in JEADV clinical practice (01-03-2024)“…Background Prurigo nodularis (PN) is a chronic, debilitating dermatologic disease characterised by the presence of highly pruritic nodular lesions. PN highly…”
Get full text
Journal Article -
3
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Published in Clinical and experimental dermatology (25-08-2023)“…BACKGROUNDTralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13…”
Get full text
Journal Article -
4
Frontal Congenital Lipoma
Published in Pediatric dermatology (01-07-2012)“…: Frontonasal dysplasia (FND) is a rare syndrome characterized by malformations of the central portion of the face, especially of the forehead, nose, and…”
Get full text
Journal Article -
5
European Surveillance System on Contact Allergies (ESSCA): Contact allergies in relation to body sites in patients with allergic contact dermatitis
Published in Contact dermatitis (01-05-2019)“…Background Analyses of the European Surveillance System on Contact Allergies (ESSCA) database have focused primarily on the prevalence of contact allergies to…”
Get full text
Journal Article -
6
European Surveillance System on Contact Allergies (ESSCA): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis
Published in Contact dermatitis (01-08-2021)“…Background Irritant contact dermatitis (ICD) is caused by the acute locally toxic effect of a strong irritant, or the cumulative exposure to various weaker…”
Get full text
Journal Article -
7
Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain
Published in International journal of dermatology (01-05-2023)“…Introduction Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin‐17 (IL‐17) receptor A and blocks the…”
Get full text
Journal Article -
8
Super responders to guselkumab treatment in moderate‐to‐severe psoriasis: a real clinical practice pilot series
Published in International journal of dermatology (01-08-2022)“…Background The term super responders defines a subset of patients with moderate‐to‐severe psoriasis that present a rapid and higher rate of response to…”
Get full text
Journal Article -
9
Drug survival, discontinuation rates, and safety profile of secukinumab in real‐world patients: a 152‐week, multicenter, retrospective study
Published in International journal of dermatology (01-05-2020)“…Background Psoriasis is a chronic systemic disease that requires long‐term management. Despite data on follow‐up studies going back 5 years, little is known…”
Get full text
Journal Article -
10
Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
Published in Life (Basel, Switzerland) (10-09-2022)“…A fast skin clearance is the main goal to achieve in psoriasis treatment. Patients that present a fast and exceptional improvement with treatment are called…”
Get full text
Journal Article -
11
Frequency of sensitization to the individual fragrances of fragrance mix I and II according to the factors included in the MOAHLFA index
Published in Contact dermatitis (01-06-2021)“…Background Fragrances constitute the second most frequent cause of allergic contact dermatitis in Spain. Objectives To determine the rate of sensitization to…”
Get full text
Journal Article -
12
Guselkumab dosing interval optimization in adult patients with moderate‐to‐severe psoriasis switching from ustekinumab
Published in Dermatologic therapy (01-11-2022)“…Psoriasis (PSO) is an inflammatory disease that emerges as a dysregulation of the interleukin 23 (IL23)/Th17 axis. There are many biologic alternatives to…”
Get full text
Journal Article -
13
Severe Atopic Dermatitis In Spain: A Real-Life Observational Study
Published in Therapeutics and clinical risk management (01-01-2019)“…To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice…”
Get full text
Journal Article -
14
Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
Published in Acta dermato-venereologica (20-11-2023)“…Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic…”
Get full text
Journal Article -
15
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved]
Published in F1000 research (2022)“…Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released…”
Get full text
Journal Article -
16
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 1; peer review: 1 approved with reservations]
Published in F1000 research (2022)“…Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released…”
Get full text
Journal Article -
17
-
18
The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: A cross-sectional study
Published in Journal of the American Academy of Dermatology (01-09-2014)“…Background The prognostic benefit of health care service provision and delivery policies for patients with malignant melanoma (MM) is not yet clear. Objective…”
Get full text
Journal Article -
19
Respuesta de los autores a la carta Las Mastocitosis en el Siglo XXI
Published in Piel (01-05-2010)Get full text
Journal Article -
20
Utilidad de la terapia fotodinámica en el tratamiento de los carcinomas basocelulares de tronco, cuero cabelludo y extremidades
Published in Piel (2011)Get full text
Journal Article